Scientists have uncovered genetic variants that help account for why weight-loss drugs such as Wegovy and Mounjaro work dramatically better for some people than others, according to findings from the journal Nature. A examination involving 15,000 people taking these medications found that those carrying specific gene variations experienced substantially greater weight loss over roughly around eight months of treatment. Whilst participants lost roughly 11.7 per cent of their body weight, some shed as much as 30 per cent whilst others experienced minimal change. The findings could also shed light on why certain individuals experience severe side-effects including nausea and vomiting. Experts suggest the genetic factors, though relatively modest in effect, work alongside other elements such as age, sex and ethnic background to determine how effectively these widely-used obesity treatments perform.
The genetic discovery transforming obesity treatment
Researchers examining data from 23andMe discovered two key genetic variants that substantially affect how well weight-loss medications work. The first variant, associated with appetite regulation and digestion, is associated with greater weight loss when taking drugs like Wegovy and Mounjaro. People carrying a single copy of this variant lose approximately 0.76 kilogrammes on average more, whilst those with two copies can multiply that extra weight loss. The variant is especially prevalent among people of European ancestry, with 64 per cent carrying one copy and 16 per cent carrying two, compared to just 7 per cent of African Americans.
The other genetic variant discovered in the study is linked to severe gastrointestinal side-effects when taking tirzepatide, the key component in Mounjaro. Researchers determined that roughly 1 per cent of people carrying this variant experience extremely intense vomiting—nearly 15 times worse than typical adverse effects. Professor Ruth Loos from the University of Copenhagen, who discussed the research, emphasised that whilst the genetic influences are relatively modest, they are comparable to other significant factors and should not be dismissed as insignificant in understanding how individuals respond to drugs.
- Genetic variants influence weight loss by approximately 0.76 kilogrammes per person
- European ancestry populations display greater frequency of weight-loss associated genes
- Second genetic variant raises risk of intense nausea and vomiting
- Genetic factors operate in conjunction with age, sex and ethnicity in influencing effectiveness
How genetic factors affect drug response
The weight loss version described
The key genetic variant found in the research acts upon the body’s appetite management and digestion, significantly impacting how weight-loss medications perform. Individuals possessing this variant show enhanced weight loss when taking drugs such as Wegovy and Mounjaro, with studies indicating an further 0.76 kilogrammes lost on average basis versus those without the variant. The mechanism appears linked to how the genes engage with the medications’ appetite-suppressing properties, boosting their efficacy in decreasing appetite and increasing satisfaction during treatment.
The influence becomes increasingly pronounced for those carrying two copies of the variant gene. These people can effectively double their additional weight loss, potentially gaining substantial benefits over those with one copy when undertaking weight management therapy. This dual-copy genetic effect constitutes a significant variation in results, particularly meaningful for patients pursuing optimal treatment outcomes. However, scientists stress that this hereditary benefit comes with a trade-off, as those affected also suffer elevated GI side-effects, such as sickness and vomiting throughout therapy.
Ancestral background and genetic patterns
The prevalence of this weight-loss-related genetic variant varies considerably across different populations, with ancestry playing a determining role in likelihood of inheritance. European ancestry populations show substantially elevated carrier rates in comparison with other ethnic groups, demonstrating genetic diversity across global populations. This disparity presents important considerations for personalised medicine approaches and understanding why weight-loss drug effectiveness may differ between individuals from different ethnic backgrounds, potentially influencing treatment planning and outcome expectations.
| Population Group | Percentage Carrying Gene Variant |
|---|---|
| European ancestry (one copy) | 64% |
| European ancestry (two copies) | 16% |
| African American (one copy) | 7% |
| African American (two copies) | Data not specified |
Understanding these hereditary patterns helps explain observed differences in medication response across diverse groups. The significantly higher prevalence of the weight-reduction variant among people of European descent suggests they may exhibit greater benefits from these drugs on average. Conversely, reduced carrier frequencies in African American communities indicate different genetic profiles that may necessitate alternative treatment strategies or adjusted expectations regarding weight-loss outcomes with existing obesity treatments.
Beyond hereditary factors: the bigger picture
Whilst inherited differences provide useful understanding into individual drug responses, researchers emphasise that inherited factors represent only one component of a considerably larger puzzle. Professor Ruth Loos notes that the hereditary influence, though modest, stays “similar to other factors – and not trivial.” This indicates that many other variables affect how successfully weight-loss medications function for each person. Sex, age, daily habits, metabolism and overall health status all play a significant role to treatment outcomes, sometimes overshadowing genetic predisposition entirely.
The multifaceted nature of personalised medicine becomes apparent when looking at the fact that 15,000 study participants shed markedly different quantities of weight despite using the same drugs. Some reduced by 30 per cent of their body weight across eight months, whilst others saw little change. This pronounced inconsistency highlights the fact that heredity in isolation is unable to forecast positive outcomes. Lifestyle elements, following prescribed treatment plans, eating patterns and individual physiology interact dynamically with genetic code to shape ultimate outcomes, indicating that a nuanced approach to weight management is essential.
- Sex differences may influence drug metabolism and weight reduction results significantly
- Age affects metabolic rate and medication effectiveness in quantifiable terms
- Ethnic background determines both genetics and environmental health influences
- Lifestyle choices and diet remain crucial despite genetic factors
- Individual health conditions interact with medication responses unpredictably
Gender, age and ethnicity variables
Sex differences play a substantive role in determining how weight-loss medications affect individuals, with recent studies suggesting men and women may respond differently to drugs like Wegovy and Mounjaro. Fluctuations in hormones, variations in body structure and different metabolic rates between sexes may affect drug bioavailability and performance. Age likewise affects treatment success, as older individuals usually display slower metabolic functioning and may experience different medication processing compared to younger patients, potentially affecting weight loss trajectories and side-effect intensity.
Ethnicity includes both genetic and socioeconomic dimensions that influence medication outcomes beyond simple genetic inheritance. Dietary customs across cultures, access to healthcare, medication affordability and lifestyle choices vary significantly across ethnic groups, all impacting weight-loss drug efficacy. Researchers recognise that understanding these intersecting variables demands thorough examination beyond genetic analysis alone, guaranteeing that upcoming therapeutic recommendations cater to diverse populations justly and successfully.
From laboratory findings to clinical practice
The discovery of genetic variations influencing weight-management medication effectiveness creates promising avenues for personalised medicine in weight management. Converting these research results into clinical practice requires careful consideration of how genetic testing could be integrated into NHS prescribing protocols and private medical services. Healthcare professionals may eventually use genetic testing to predict which individuals will show the best response to specific medications, potentially enhancing clinical results and minimising unwanted adverse effects. However, implementing such screening across the system poses logistical and financial challenges that the NHS must tackle systematically.
Current obesity treatment continues to be largely one-size-fits-all, with patients being prescribed identical medications regardless of their genetic makeup. As genetic understanding advances, clinicians could tailor prescriptions to individual genetic profiles, maximising weight loss whilst reducing unwanted side effects. This shift towards precision medicine demands investment in genetic testing infrastructure, clinician education programmes and updated clinical guidelines. The research indicates that whilst genetic factors contribute modestly, their identification alongside monitoring of other variables could substantially improve treatment efficacy and client outcomes across diverse populations.
The targeted medicine potential
Precision medicine constitutes a significant departure from uniform therapeutic approaches towards tailored patient care based on genetic and phenotypic characteristics. By determining which patients possess beneficial genetic variants, clinicians could improve drug choice and treatment dosages, consequently improving weight loss outcomes whilst minimising nausea and vomiting side effects. This approach offers better resource allocation, better patient outcomes and increased certainty in obesity treatment across the NHS and independent healthcare.
- Genetic screening could predict how individual patients respond to drugs reliably
- Personalised dosing regimens might decrease harmful side effects considerably
- Precision approaches optimise treatment satisfaction and patient outcomes substantially
What this means for service users today
For the many people currently taking weight-loss medications like Wegovy and Mounjaro, these genetic discoveries offer valuable understanding into why their outcomes vary so dramatically. Whilst genetic factors represent only a limited effect on treatment success, they work alongside other significant variables including sex, age and cultural origin to shape personal results. Understanding these trends helps clarify why some patients see substantial weight losses of 30 per cent or more, whilst others see scant improvement despite taking equivalent treatments. This knowledge validates the disappointment patients widely experience when treatments do not produce expected benefits, suggesting biological factors rather than individual shortcoming play a significant role.
Currently, the NHS and independent healthcare providers prescribe weight-loss drugs in the absence of genetic testing, meaning patients receive standardised treatment irrespective of their individual genetic profile. The majority of individuals taking these drugs remain unaware whether they carry genetic variants that could predict their response or vulnerability to side-effects such as severe nausea. Whilst genetic testing is not yet routinely available through the NHS, this research provides a basis for future bespoke treatment methods. Patients talking through treatment options with healthcare providers can now recognise that their genetic profile could affect outcomes, which may prompt more informed conversations about realistic expectations and individual risk factors before starting medication.